Table 3.
Cytotoxicity of 19a against Individual NCI-60 Cell Lines
| panel | cell line | GI50 (μM)a | panel | cell line | GI50 (μM) |
|---|---|---|---|---|---|
| MGMb | 0.145 | colon cancer | COLO 205 | 0.144 | |
| leukemia | CCRF-CEM | 0.144 | HCC-2998 | 0.63 | |
| K-562 | 0.156 | HCT116 | 0.0855 | ||
| MOLT-4 | 0.118 | HCT-15 | 0.427 | ||
| RPMI-8226 | 0.14 | HT29 | 0.149 | ||
| SR | 0.0669 | KM12 | 0.875 | ||
| non-small cell lung cancer | A549/ATCC | 0.244 | SW-620 | 0.345 | |
| EKVX | 0.79 | renal cancer | 786-0 | 0.166 | |
| HOP-62 | 0.18 | A498 | 0.347 | ||
| HOP-92 | 0.558 | ACHN | 0.16 | ||
| NCI-H226 | 0.512 | CAKI-1 | 0.186 | ||
| NCI-H23 | 0.201 | RXF 393 | 0.516 | ||
| NCI-H322M | 0.428 | SN 12C | 0.258 | ||
| NCI-H460 | 0.141 | TK-10 | 0.722 | ||
| NCI-H522 | 0.076 | UO-31 | 0.157 | ||
| CNS cancer | SF-268 | 0.283 | breast cancer | MCF7 | 0.118 |
| SF-295 | 0.177 | MDA-MB-231/ATCC | 0.826 | ||
| SF-539 | 0.186 | HS 578T | 1.86 | ||
| SNB-19 | 0.233 | BT-549 | 0.291 | ||
| SNB-75 | 0.239 | T-47D | 0.111 | ||
| U251 | 0.14 | MDA-MB-468 | 0.14 | ||
| melanoma | LOX IMVI | 0.112 | ovarian cancer | IGROV1 | 0.312 |
| MALME-3M | 0.284 | OVCAR-3 | 0.582 | ||
| M14 | 0.149 | OVCAR-4 | 0.557 | ||
| MDA-MB-435 | 0.395 | OVCAR-5 | 0.595 | ||
| SK-MEL-2 | 0.886 | OVCAR-8 | 0.554 | ||
| SK-MEL-28 | 0.861 | NCI/ADR-RES | 0.29 | ||
| SK-MEL-5 | 0.181 | SK-OV-3 | 0.24 | ||
| UACC-257 | 0.528 | prostate cancer | PC-3 | 0.317 | |
| UACC-62 | 0.0966 | DU-145 | 0.215 |
a
GI50 values were defined as the compound concentrations that resulted in 50% cell growth inhibition. The cells were incubated for 2 days with the tested compounds.
b
MGM: mean graph midpoint for growth inhibition of all human cancer cell lines.